Contrave heart safety under microscope in 8,600-Patient trial
Disease control
Ongoing
This study is testing whether the weight-loss medication Contrave (naltrexone/bupropion) increases the risk of serious heart problems like heart attack, stroke, or heart-related death. About 8,600 obese or overweight adults with heart risk factors are taking either Contrave or a …
Phase: PHASE4 • Sponsor: Currax Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:50 UTC